查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1629900

全球一次性自动注射器市场 - 2025-2033

Global Disposable Autoinjectors Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球一次性自动注射器市场达到7.123亿美元，预计到2033年将达到30.732亿美元，2025-2033年预测期间复合年增长率为17.8%。

一次性自动注射器是一种设计用于皮下或肌肉内自我给药的医疗设备，通常采用预填充注射器的形式。这些设备的特点是一次性使用，这意味着它们在註射药物后就会被丢弃。使用者只需将自动注射器靠在皮肤上，然后透过简单的推动即可启动它。然后，该设备透过隐藏在设备内的针头自动输送药物，针头在使用后立即缩回，以确保安全并防止针刺伤。

一次性自动注射器市场的需求正在经历显着成长。例如，根据美国国立卫生研究院 (NIH) 的数据，已有 20 多家製药公司开发了近 80 种自动注射器。近 50 种药物被开发为使用自动注射器给药的组合产品。其中，62%的自动注射器是一次性的。由于慢性病盛行率不断上升、药物配方的进步以及自我给药的推动等几个关键因素，一次性自动注射器的市场需求一直在稳步增长。

市场动态：

驱动程式和限制

慢性病盛行率上升

慢性病盛行率的上升极大地推动了一次性自动注射器市场的成长，预计将在预测期内推动该市场的成长。随着全球糖尿病发生率的上升，对自动注射器等胰岛素输送系统的需求不断增加。例如，根据世界卫生组织 (WHO) 的数据，全球约有 8.3 亿人患有糖尿病，其中大多数生活在低收入和中等收入国家。糖尿病患者数量的不断增加推动了对自动注射器进行胰岛素注射的需求，因为自动注射器为患者在家注射胰岛素提供了一种方便、更安全的方法，这对于控制病情至关重要。

越来越多地使用生物製剂和单株抗体来治疗自体免疫疾病和癌症，刺激了对自动注射器的需求。这些药物需要自动注射器提供的精确剂量和可靠给药。用于治疗类风湿性关节炎和其他自体免疫疾病的 Humira Pen 等设备的推出体现了市场对生物製剂的反应，表明对患者友好型自我给药设备的需求不断增加。

糖尿病、类风湿性关节炎、多发性硬化症等各种慢性疾病的盛行率不断上升，由于其便利性和谨慎管理病情的能力，自我给药的显着转变。一次性自动注射器迎合了这一趋势，允许患者在家中给药，而无需医疗保健提供者干预。

例如，2024年1月，大正製药株式会社宣布推出TNFa抑制剂Nanozora 30 mg一次性皮下注射自动注射器（通用名：ozoralizumab（重组））。此药物采用的装置考虑了类风湿性关节炎（RA）患者的易用性。 Taisho 旨在为 RA 患者提供新的治疗选择，提供 Nanozora 30mg 皮下注射注射器和 Nanozora 30mg 皮下注射自动注射器。

替代药物传输系统的可用性

替代药物输送系统的出现预计将阻碍一次性自动注射器市场的成长。这些替代方案包括传统的注射器注射、吸入器和其他形式的药物输送，可以提供竞争优势，例如成本效益、易用性和不同的治疗体验。

传统注射器仍然是一种具有成本效益的药物输送选择，特别是在资源匮乏的环境中。它们广泛使用且为医疗保健提供者和患者所熟悉，使其成为一次性自动注射器的有吸引力的替代品。例如，在某些地区，使用一次性自动注射器的成本可能比传统注射器高得多，这可能会阻碍采用。在预算有限的医疗保健系统中，对传统注射器的偏好可能会减缓自动注射器的使用。

Auvi-Q 等品牌肾上腺素自动注射器的通用且低成本替代品已获得关注。这些替代品以较低的价格提供相似的功效，使更广泛的患者群体更容易获得它们。这种竞争可能会减少品牌一次性自动注射器的市场份额，因为注重成本的消费者会选择更实惠的选择。

针对荷尔蒙替代疗法和慢性疼痛管理等病症的透皮贴片提供了完全避免注射的替代方案。这些贴片可在较长时间内透过皮肤输送药物，无需使用针头和自动注射器。对此类贴片的日益接受可以减少对一次性自动注射器的需求。例如，治疗帕金森氏症的 Neupro 贴片为某些患者提供了自动注射器治疗的可行替代方案。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按类型分類的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 慢性病盛行率上升
      • 不断进步的技术
    • 限制
      • 替代药物传输系统的可用性
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：一次性自动注射器市场（按类型）

  • 预充式自动注射器
  • 可填充自动注射器

第 6 章：一次性自动注射器市场（按应用）

  • 糖尿病
  • 类风湿关节炎
  • 多发性硬化症
  • 过敏反应
  • 其他的

第 7 章：一次性自动注射器市场（按最终用户）

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他的

第 8 章：一次性自动注射器市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 9 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 10 章：公司简介

  • Becton, Dickinson, and Company
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Ypsomed AG
  • Owen Mumford Inc.
  • Phillips Medisize
  • SHL Medical
  • Stevanato Group
  • Faxne
  • Dali Medical Devices

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD8934

The global disposable autoinjectors market reached US$ 712.3 million in 2024 and is expected to reach US$ 3,073.2 million by 2033, growing at a CAGR of 17.8% during the forecast period 2025-2033.

A disposable autoinjector is a medical device designed for the subcutaneous or intramuscular self-administration of medication, which is typically in the form of a pre-filled syringe. These devices are characterized by their single-use nature, meaning they are disposed of after the medication has been injected. The user simply positions the autoinjector against the skin and activates it with a simple push. The device then automatically delivers the medication via a needle hidden within the device, which retracts immediately after use to ensure safety and prevent needle-stick injuries.

The demand for disposable autoinjectors market is experiencing significant growth. For instance, according to the National Institute of Health (NIH), more than 20 pharmaceutical companies have developed nearly about 80 autoinjectors. Nearly 50 drugs are developed as combination products for administration using autoinjectors. Among these, 62% of the autoinjectors are disposable. The market demand for disposable autoinjectors has been steadily increasing due to several key factors including the growing prevalence of chronic diseases, advancements in drug formulations and the push towards self-administration.

Market Dynamics: Drivers & Restraints

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases is significantly driving the growth of the disposable autoinjectors market and is expected to drive the market over the forecast period. With the global rise in diabetes, the demand for insulin delivery systems like autoinjectors has increased. For instance, according to the World Health Organization (WHO), about 830 million people worldwide have diabetes, the majority living in low-and middle-income countries. The rising number of diabetes patients is driving demand for autoinjectors for insulin administration as autoinjectors offer a convenient and safer method for patients to administer insulin at home, which is crucial for managing the condition.

The growing use of biologics and monoclonal antibodies for treating autoimmune diseases and cancer has spurred demand for autoinjectors. These drugs require precise dosing and reliable administration, which autoinjectors provide. The introduction of devices like the Humira Pen for rheumatoid arthritis and other autoimmune diseases exemplifies the market's response to biologics, showing an increased demand for patient-friendly, self-administration devices.

The increasing prevalence of various chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis and others is a notable shift towards self-administration due to its convenience and the ability to manage conditions discreetly. Disposable autoinjectors cater to this trend by allowing patients to administer their medications at home without the need for healthcare provider intervention.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. announced that the Nanozora 30 mg Disposable Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFa inhibitor is launched. The drug employs a device that considers ease of use for patients with rheumatoid arthritis (RA). Taisho aims to provide new treatment options for patients with RA, offering Nanozora 30mg Syringes for S.C. Injection and Nanozora 30mg Autoinjector for S.C. Injection.

Availability of alternative drug delivery systems

The availability of alternative drug delivery systems is expected to hamper the growth of the disposable autoinjectors market. These alternatives, which include traditional syringe injections, inhalers and other forms of drug delivery, can offer competitive advantages such as cost-effectiveness, ease of use and different treatment experiences.

Traditional syringes remain a cost-effective option for drug delivery, especially in low-resource settings. They are widely available and familiar to both healthcare providers and patients, making them an attractive alternative to disposable autoinjectors. For instance, in some regions, the cost of using disposable autoinjectors can be significantly higher compared to conventional syringes, which can deter adoption. In healthcare systems where budgets are limited, the preference for traditional syringes can slow the uptake of autoinjectors.

Generic and low-cost alternatives to branded epinephrine autoinjectors, like Auvi-Q, have gained traction. These alternatives offer similar efficacy at a lower price point, making them more accessible to a broader patient population. This competition can reduce the market share of branded disposable autoinjectors, as cost-conscious consumers opt for more affordable options.

Transdermal patches for conditions like hormone replacement therapy and chronic pain management offer an alternative that avoids injections altogether. These patches deliver medication through the skin over an extended period, bypassing the need for needles and auto-injectors. The growing acceptance of such patches can reduce the demand for disposable auto-injectors. For example, the Neupro patch for Parkinson's disease provides a viable alternative to auto-injector treatments for some patients.

Segment Analysis

The global disposable autoinjectors market is segmented based on type, application, end-user and region.

Product Type:

The prefilled autoinjectors segment is expected to dominate the disposable autoinjectors market share

Prefilled autoinjectors are designed for ease of use, allowing patients to self-administer medications without the need for healthcare provider assistance. These devices typically come pre-filled with the medication, eliminating the need for patients to fill the device themselves. The design of prefilled autoinjectors, such as those used for insulin delivery and other medications, simplifies the administration process and reduces the potential for user error.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. launched the Nanozora 30 mg Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFa inhibitor. Nanozora 30mg Autoinjector for S.C. Injection is a single-use autoinjector dosage form, prefilled with the same drug as the syringe dosage form Nanozora 30mg Syringe for S.C. Injection. Users can easily inject the drug simply by pressing the injector against the skin. The needle covering will be locked after injection to prevent needle-piercing accidents.

Many prefilled autoinjectors come equipped with smart features such as Bluetooth connectivity for monitoring injection history and dosage reminders. These features enhance patient management and engagement by providing real-time data to patients and healthcare providers. These smart devices also allows patients to monitor their medication usage and receive reminders, making it a preferred choice over traditional devices.

For instance, in May 2022, Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, signed an exclusive agreement with leading medical device developer and manufacturer Owen Mumford Ltd. for its Aidaptus auto-injector. Aidaptus is a 2-step, single-use auto-injector with a versatile design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device.

Geographical Analysis

North America is expected to hold a significant position in the disposable autoinjectors market share

North America, particularly the United States, boasts a highly developed healthcare infrastructure, which includes advanced hospitals, research facilities, and specialized clinics. This infrastructure supports the adoption of advanced drug delivery technologies such as disposable auto-injectors. For instance, major healthcare providers and facilities across the U.S. utilize auto-injectors for treating conditions like rheumatoid arthritis and multiple sclerosis, which are common in the region. This widespread usage creates a strong demand for disposable autoinjectors.

For instance, in May 2021, Phillips-Medisize, a Molex company, unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation and sustainability in the digital drug delivery device market. This latest advancement introduces a small smart injection device featuring single-use disposable cassettes to elevate patient care while reducing environmental impact.

In the U.S., self-administration of medications using auto-injectors has been widely adopted for chronic disease management. For example, therapies for rheumatoid arthritis and multiple sclerosis are commonly delivered via auto-injectors like the Sensoready and Rebif, respectively. The convenience and safety of these devices make them highly preferred among patients, contributing to the dominance of North America in this market.

Asia-Pacific is growing at the fastest pace in the disposable autoinjectors market

Countries in the APAC region, particularly China and India, are witnessing substantial increases in healthcare spending as governments allocate more resources towards improving healthcare infrastructure. For instance, China's National Healthcare Security Administration has been expanding insurance coverage to include more advanced medical devices like auto-injectors. This expansion boosts the adoption of these devices across the region.

There is growing awareness among patients in the APAC region regarding the benefits of self-administered therapies. This awareness is being driven by healthcare campaigns, education programs, and the increased availability of auto-injectors through pharmacies and healthcare facilities. For instance, countries like India are seeing increased awareness about the benefits of using prefilled auto-injectors for treating conditions like rheumatoid arthritis.

The younger generation in the APAC region is more inclined towards modern technologies, including those related to healthcare. This demographic trend supports the adoption of auto-injectors over traditional methods. The increasing urbanization and better education levels are also factors contributing to higher acceptance rates of self-administered injectables.

Competitive Landscape

The major global players in the disposable autoinjectors market include Becton, Dickinson, and Company, Ypsomed AG, Owen Mumford Inc., Phillips Medisize, SHL Medical, Stevanato Group, Faxne, Dali Medical Devices and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global disposable autoinjectors market report delivers a detailed analysis with 56 key tables, more than 52 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Chronic Diseases
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Availability of Alternative Drug Delivery Systems
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Disposable Autoinjectors Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Prefilled Autoinjectors*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Fillable Autoinjectors

6. Disposable Autoinjectors Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Rheumatoid Arthritis
  • 6.4. Multiple Sclerosis
  • 6.5. Anaphylaxis
  • 6.6. Others

7. Disposable Autoinjectors Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Disposable Autoinjectors Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Becton, Dickinson, and Company*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Ypsomed AG
  • 10.3. Owen Mumford Inc.
  • 10.4. Phillips Medisize
  • 10.5. SHL Medical
  • 10.6. Stevanato Group
  • 10.7. Faxne
  • 10.8. Dali Medical Devices

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us